Novavax Transfers EU Vaccine Rights to Sanofi

Novavax ( (NVAX) ) has issued an update.

On October 1, 2025, the European Commission approved the transfer of the marketing authorization for Novavax‘s COVID-19 vaccine, Nuvaxovid, from Novavax CZ to Sanofi Winthrop Industrie. This transfer, part of the company’s collaboration and license agreement with Sanofi, triggered a $25 million milestone payment to Novavax, expected in the first quarter of 2026. This move allows Sanofi to take full responsibility for commercial and regulatory activities in the EU, furthering Novavax’s strategy of ensuring global access to its vaccine. The agreement also includes potential future milestone payments and royalties for Novavax, highlighting the ongoing collaboration with Sanofi and its impact on Novavax’s operations and market positioning.

The most recent analyst rating on (NVAX) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.

Spark’s Take on NVAX Stock

According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.

Novavax’s overall stock score is primarily impacted by financial instability and mixed technical indicators. However, positive earnings call sentiment and strategic corporate events provide some support.

To see Spark’s full report on NVAX stock, click here.

More about Novavax

Novavax, Inc. is a biotechnology company focused on developing vaccines to address some of the world’s most pressing health challenges. The company utilizes its scientific expertise and proven technology platform, which includes protein-based nanoparticles and the Matrix-M adjuvant, to create vaccines. Novavax’s growth strategy involves optimizing existing partnerships, expanding access to its technology platform, and pursuing new collaborations in infectious diseases and beyond.

Average Trading Volume: 6,291,670

Technical Sentiment Signal: Hold

Current Market Cap: $1.47B

Find detailed analytics on NVAX stock on TipRanks’ Stock Analysis page.